Long‐term follow‐up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

• DOI: 10.1002/cncr.29990
• Publication Date: 2016-03-29T01:22:47Z
• Authors: Tomasz Czerw; Myriam Labopin; Norbert‐Claude Gorin; Sebastian Giebel; Didier Blaise; Giovanna Meloni; Arnaud Pigneux; Alberto Bosi; Joan Veelken; Felicetto Ferrara; Nicolaas Schaap; Roberto M. Lemoli; Jan J. Cornelissen; Eric Beohou; Arnon Nagler; Mohamad Mohty
• Keywords: Autologous stem-cell transplantation

Leukemia recurrence is a major cause of treatment failure after autologous stem cell transplantation for acute myeloid leukemia (AML). It usually occurs within the first 2 years transplantation. The goal current retrospective study was to assess follow-up and characterize risk factors outcome among patients who survived free disease this period.The analysis included 3567 adults (median age, 45 years) with AML underwent autografting during (86% patients) or second (14% complete remission between 1990 2008. source bone marrow in 32% peripheral blood 68% patients. median 6.9 years.At 5 10 transplantation, probability leukemia-free survival 86% 76%, respectively; incidence 11% 16%, nonrecurrence mortality rate 3% 8%, respectively. observed decreased compared expected general European population. In multivariate analysis, demonstrated transplantation; had French-American-British subtypes M0, M6, M7; were an older age. same found be associated increased recurrence. Nonrecurrence affected by age.The results indicate that late recurrences remain concern AML, indicating need close monitoring minimal residual additional leukemic control measures Cancer 2016;122:1880-7. © 2016 American Society.